Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Pogeu Mahone

To: mplaut who wrote (12232)	7/15/2013 1:18:06 PM
From: NTTG	1 Recommendation of 13111

I understood it was not your list. several PII and small series studies have looked at Bleomycin + ECT - in general CR in 75/84 lesions, PR in 8/84....did not prevent new lesions from forming J Am Acad Dermatol. 2011 Feb;64(2):413-22. doi: 10.1016/j.jaad.2009.12.013. Epub 2010 Mar 23. Older literature is available on 5-FU and methotrexate, also with better CR/PR in stage III and IV patients

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next